港交所(00388.HK)續升3.5%曾逼近391元 傳港股通擴至生物科技及第二上市股
市傳施政報告將公布擴中港「互聯互通」範圍至生物科技及第二上市股。港交所(00388.HK)四連升,尤其是今天跑贏大市和大部分藍籌,最高見390.8元,現造390元,續升3.5%,成交增至532萬股,涉資20.55億元。
特首林鄭月娥與早前訪京爭取中央惠港措施,新一份施政報告因而延至明天(25日)公布。據《星島日報》報道,中央支持的其中一項惠港金融措施,是擴大「互聯互通」計劃。據報實施六年的滬深港通機制,將擴大涵蓋範圍,內地投資者南下資金,將可買賣本港上市的生物科技股及第二上市股份,「北水」將可投資阿里巴巴(09988.HK)、京東(09618.HK)、網易(09999.HK)等重磅科技股。
此外,港交所公布開發滬深港通交易結算加速平台HKEX Synapse,進一步提高滬深港通交易結算效率。Synapse將利用DAML智能合約簡化滬深港通北向交易的交易後工作流程,以透明、安全和可靠方式提高市場參與者的結算效率和結算能力,旨在幫助資產管理機構、證券經紀、全球及本地託管機構和結算參與者,更加高效地處理不斷增長滬深港通交易量帶來結算工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.